Orlistat, an under-recognised cause of progressive renal impairment.
Obesity is an emerging risk factor for chronic kidney disease (CKD) in the developed world. Orlistat, an intestinal lipase inhibitor, used in the treatment of obesity is available as an over-the-counter medication across the European union and in many countries worldwide. It is associated with acute kidney injury (AKI). We present three adults, followed up from 1 to 6 years, who developed de novo or worsening renal impairment while on orlistat. Stopping the drug halted progression, but did not reverse the degree of renal impairment at presentation.
Renal Specialist Registrar, Renal Unit, Ipswich General Hospital, The Ipswich Hospital NHS Trust, Ipswich, Suffolk, UK.
Andrew K
AK
Coutinho
Gerald R
GR
Glancey
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis; D000368:Aged; D019440:Anti-Obesity Agents / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D018450:Disease Progression; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D007783:Lactones / Q000009:adverse effects*; D008049:Lipase / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D011379:Prognosis; D012307:Risk Factors
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat; D008049:Lipase
kidney disease; obesity; orlistat